AmberGen | GenomeWeb

AmberGen

Universidad del Pais Vasco of Leioa-Vizcaya, Spain, has been awarded US Patent No. 8,486,637, "Methods and reagents for the detection of Salmonella spp."

MDxHealth and GlaxoSmithKline Biologicals, both of Belgium, have been awarded US Patent No. 8,481,700, "Detection of MAGE-A expression."
Ilse Vlassenbroeck and Katja Bierau are named as inventors.

Panasonic of Osaka, Japan, has received US Patent Nos.

AmberGen is developing a microbead-based, multiplexed, in vitro pediatric allergy test. The diagnostic is designed to enable the detection of multiple allergen-specific IgE antibodies in blood, according to a company executive.

Microarray-Related NIH Grants, Jan. 1 – May 10, 2012

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – AmberGen will provide its proprietary photocleavable biotin reagent for the commercial use with SomaLogic's Somascan technology platform under a deal announced on Tuesday.

Winners of NCI's Bridge awards, which give up to $3 million to cross the biomedical business 'valley of death', include 20/20 GeneSystems, Ambergen, and Advanced Cell Diagnostics.

Paired Ends

Premium

Christopher Sears

Patents of Note

Premium

Sequencing-Related US Patents Granted May 20 – June 23

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.